Generated November 2026 · Clinical Deep Dive 0 Comments Your fibromyalgia patient has a diagnosis, a playbook, and a prescription. Only some of that stands on firm ground. The FDA has approved four drugs for fibromyalgia, European regulators refused the first three, and no European application has been identified forContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
LYON, France — Halving the dose of antenatal betamethasone given to prevent severe respiratory distress syndrome (RDS) in infants does not appear to affect later intelligence quotient (IQ) scores or other measures of neurodevelopment, suggests a follow-up study of a randomized trial. However, it is unclear from the present data…ReadContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis whoContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
🛡️ Just a quick check We’re checking your connection to prevent automated abuse Read MoreContinue Reading
Skip to content